Written by Benjamin L. Maughan, MD, PharmD, & Lawrence I. Karsh, MD,
Metastatic castration-sensitive prostate cancer (mCSPC) is incurable, and the aim of treatment is tumor suppression to prolong survival.1For patients with mCSPC, androgen deprivation therapy alone (ADT) continues to be used widely despite the availability of newer and more effective therapies. Androgen receptor pathway inhibitors, also known as ARPIs, in combination with ADT, have become available over the last decade. Clinical trials of ARPIs show that these treatments are more efficacious as life-prolonging therapies for patients with mCSPC than ADT alone.2-6
Ask an Expert